%0 Journal Article
%A Zhang, Yiyao
%A Liu, Lizhen
%A Fan, Pei
%A Bauer, Nathalie
%A Gladkich, Jury
%A Ryschich, Eduard
%A Bazhin, Alexandr V
%A Giese, Nathalia A
%A Strobel, Oliver
%A Hackert, Thilo
%A Hinz, Ulf
%A Gross, Matthias Wolfgang
%A Fortunato, Franco
%A Herr, Ingrid
%T Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
%J OncoTarget
%V 15
%N 1
%@ 1949-2553
%C [Erscheinungsort nicht ermittelbar]
%I Impact Journals LLC
%M DKFZ-2024-01494
%P 504 - 506
%D 2024
%Z Original article: Oncotarget. 2015; 6:9999–10015. https://doi.org/10.18632/oncotarget.3171
%K Humans
%K Gemcitabine
%K Deoxycytidine: analogs & derivatives
%K Deoxycytidine: pharmacology
%K Deoxycytidine: therapeutic use
%K Pancreatic Neoplasms: drug therapy
%K Pancreatic Neoplasms: pathology
%K Pancreatic Neoplasms: metabolism
%K Drug Resistance, Neoplasm: drug effects
%K Aspirin: pharmacology
%K Aspirin: therapeutic use
%K Neoplastic Stem Cells: drug effects
%K Neoplastic Stem Cells: pathology
%K Neoplastic Stem Cells: metabolism
%K Antimetabolites, Antineoplastic: pharmacology
%K Gemcitabine (NLM Chemicals)
%K Deoxycytidine (NLM Chemicals)
%K Aspirin (NLM Chemicals)
%K Antimetabolites, Antineoplastic (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39018218
%R 10.18632/oncotarget.28527
%U https://inrepo02.dkfz.de/record/291690